The Multiple Myeloma Research Consortium and Nereus Pharmaceuticals, Inc. Initiate Clinical Trial Investigating NPI-0052 to Treat Multiple Myeloma

SAN DIEGO and NORWALK, Conn., April 16 /PRNewswire/ -- The Multiple Myeloma Research Consortium (MMRC) and Nereus Pharmaceuticals, Inc., a pioneer in drug discovery and development from marine microbial sources, today announced the enrollment of the first patient in a multi-center Phase I clinical trial to study Nereus' novel, second generation proteasome inhibitor NPI-0052 in patients with multiple myeloma.